Literature DB >> 29780706

The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.

Lore Decoster1, Philippe Giron1, Sacha Mignon1, Jacques De Grève1.   

Abstract

Entities:  

Year:  2018        PMID： 29780706      PMCID： PMC5943217          DOI： 10.21037/tlcr.2018.03.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

2.  Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Authors:  Satomi Watanabe; Hidetoshi Hayashi; Kazuhiko Nakagawa
Journal:  Ann Transl Med       Date:  2016-06

3.  Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

Authors:  Jacques De Grève; Teresa Moran; Marie-Pascale Graas; Daniella Galdermans; Peter Vuylsteke; Jean-Luc Canon; Denis Schallier; Lore Decoster; Erik Teugels; Dan Massey; Vikram K Chand; Johan Vansteenkiste
Journal:  Lung Cancer       Date:  2015-01-23       Impact factor: 5.705

4.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

5.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

6.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Authors:  J De Grève; E Teugels; C Geers; L Decoster; D Galdermans; J De Mey; H Everaert; I Umelo; P In't Veld; D Schallier
Journal:  Lung Cancer       Date:  2012-02-10       Impact factor: 5.705

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Authors:  M G Kris; D R Camidge; G Giaccone; T Hida; B T Li; J O'Connell; I Taylor; H Zhang; M E Arcila; Z Goldberg; P A Jänne
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976

9.  A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.

Authors:  J J Yang; Q Zhou; H H Yan; X C Zhang; H J Chen; H Y Tu; Z Wang; C R Xu; J Su; B C Wang; B Y Jiang; X Y Bai; W Z Zhong; X N Yang; Y L Wu
Journal:  Br J Cancer       Date:  2017-01-19       Impact factor: 7.640

Review 10.  Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

Authors:  Jon Zugazagoitia; Asunción Díaz; Elisabeth Jimenez; Juan Antonio Nuñez; Lara Iglesias; Santiago Ponce-Aix; Luis Paz-Ares
Journal:  Front Med (Lausanne)       Date:  2017-04-05
View more
  2 in total

1.  Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.

Authors:  Sheng-Jie Sun; Jin-Di Han; Wei Liu; Zhi-Yong Wu; Xiao Zhao; Xiang Yan; Shun-Chang Jiao; Jian Fang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

2.  Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody.

Authors:  Junjun Zhang; Jing Lou
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-12       Impact factor: 2.650
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.